Daikin Industries (6367)

Signal panel

Investment thesis

1. [Reported fact / inference] The core profit engine has not turned convincingly. Q1 external HVAC revenue was ¥1,325.051bn and OP ¥118.234bn; its margin fell from approximately 10.1% to 8.9%, and OP excluding FX was 99% of the prior year [Q pp.5–6; Q1 pp.4–6,16]. Chemicals supplied ¥4.933bn, or a calculated 53% of the ¥9.260bn consolidated OP increase, despite being much smaller [FS, quarterlySegments].
2. [Company guidance / inference] FUSION30 is measurable, not yet earned. It targets 10% operating margin and 12% ROE in company FY2028, meaning the year ending March 2029; current FY2026/03 actuals are 8.3% and 9.1%. Company FY2030, ending March 2031, projects 12% margin and 15% ROE [S pp.7,13–14]. These targets should not be capitalized as achieved earnings.
3. [External estimate / inference] The pullback is not a deep-value signal. The shares are 19.3% below their 52-week high, but the one-year-forward consensus PER is only 0.66 standard deviations below its recent mean. FY2028/03 consensus OP of ¥500.047bn already assumes substantial recovery and has been revised down 2.8% over three months [FS, price/valuation/consensus].

Business and earnings

[Reported fact] Customers buy residential and commercial air conditioners, refrigeration equipment, applied cooling systems, controls and services; the second business supplies fluorochemicals. FY2026/03 external HVAC sales were ¥4,621.131bn and OP ¥376.991bn, versus chemicals sales ¥281.469bn and OP ¥33.089bn [FY pp.4–6]. Distribution, engineering, efficient equipment and the ability to integrate installation and service support differentiation; the economic durability of that advantage must ultimately appear in margins and returns, not market-share language alone [Q pp.8–11; inference].

[Reported fact, secondary geography] Overseas revenue was 83.9%: US 35.6%, Europe 17.1%, Japan 16.1%, Asia/Oceania 14.2%, China 9.4% [FS, regions]. The business therefore combines construction/replacement cycles, weather, financing costs, energy-efficiency regulation, refrigerant transitions and FX exposure rather than a single global demand cycle.

[Reported fact] FY2026/03 sales rose 5.5% to ¥5,015.036bn and OP 3.3% to ¥414.991bn; margin slipped to 8.3%. Standalone Q4 OP rebounded 29.1%, but Q1 FY2027/03 sales of ¥1,426.810bn, OP ¥130.560bn and NP ¥80.136bn represented +17.5%, +7.6% and −1.7% respectively; margin fell to 9.2% from 10.0% [FY p.1; Q1 p.1; FS, quarters]. IFIS rounds sales growth to 17.6%; the filing's 17.5% is used here.

[Reported fact] Q1's OP bridge was FX +¥5.5bn; materials/tariffs/logistics −¥38.0bn; fixed costs/other −¥18.5bn; sales expansion +¥17.8bn; pricing +¥25.0bn; savings +¥17.5bn. The materials bucket includes direct tariff costs of ¥4.6bn and tariff refunds of ¥10.5bn [Q p.6]. [Inference] Subtracting only the refund gives approximately ¥120.06bn OP, about 1.0% below the prior year's ¥121.30bn; subtracting FX as well gives ¥114.56bn, about 5.6% below. These are analytical sensitivities, not company adjusted profit, and do not establish whether refunds will recur. Refund eligibility, period attribution and recurrence are not fully resolved.

[Reported fact / management commentary] Regional evidence is uneven:

• US residential DNA revenue increased 2% in local currency: volume +10 percentage points, pricing +2 and mix/other −10. This is not premium-mix-led growth [T p.15]. Applied sales rose 17% in local currency, but North American HVAC margin fell two points [Q pp.9,17].
• Europe revenue rose 8% in local currency versus 23% in yen; heating volume rose 7%, while Applied sales fell 10% in local currency [Q pp.11,23].
• China sales rose 4% in yen but fell 12% in local currency; FX masks weak underlying demand [Q pp.10,23].
• Chemicals benefited from high-profit applications and distributor restocking, not solely final demand [Q p.5; T p.20].

[Reported fact / inference] The October 14 Phoenix announcement increases modular-system production capacity approximately 150%, with footprint expanding from 58,000 to 191,000 square feet. This supports a real capacity opportunity across data centers, healthcare and industry, but no incremental revenue, backlog or OP was supplied; it is not evidence that AI cooling is already material to consolidated profit [Phoenix release]. Quantitative orders and backlog sufficient to calculate book-to-bill were not available in the reviewed documents; no order-led recovery conclusion is made.

Forecast test

Sources: Q1 pp.1,7; FS, guidance/consensus. Company guidance assumes USD/JPY145, EUR/JPY170 and CNY/JPY21.0 [Q p.26].

[External estimate / inference] OP progress is 29.9%, only +1.26 percentage points above the median 28.7% of prior same-quarter guidance progress. NP progress is 28.8%, −1.36 points below its 30.2% median. The baseline covers FY2023/03–FY2026/03 and uses guidance in force at each announcement; no irregular-period/accounting-standard breaks were identified [FS, progress; factsheet.json, breaks=[]]. This is normal seasonal progress, not a compelling upward-revision setup. Removing the refund is an earnings-quality sensitivity, not a replacement historical seasonal series.

[Reported fact / secondary history] Actual OP missed initial guidance by 2.0%, 5.5% and 4.6% in the latest three fiscal years. Earlier strong beats, including the pandemic recovery, do not justify assuming habitual conservatism today [FS, guidance]. Management deferred revision pending the peak Q2 season [T pp.4–5].

[Unknown / inference] A reliable after-tax EPS adjustment for the refund requires tax and attribution information not obtained; no invented normalized EPS is presented. Guidance ordinary profit is below OP, so there is no apparent large non-operating-gain uplift of the sort flagged by the methodology. That does not remove the OP-level refund issue. Price implementation, copper exposure, tariffs and geographic mix remain forecast risks [Q p.6; T p.19].

Financial strength and capital allocation

[Reported fact] FY2026/03 OCF was ¥465.848bn versus NP ¥275.229bn; OCF plus investing CF was ¥143.609bn. OCF was positive in all latest three years: ¥399.567bn, ¥514.450bn and ¥465.848bn [AR p.2; FY p.16]. FY2026/03 receivables absorbed ¥80.315bn cash; balance-sheet receivables rose 18.0% versus sales growth of 5.5%, with translation/consolidation effects preventing a direct one-for-one reconciliation [FY p.16; FS, flags].

[Reported fact / inference] March-end cash/deposits of ¥933.484bn and debt ¥1,094.653bn gave net debt ¥161.169bn, only 5.0% of equity [FS, balance]. That is a pre-buyback balance sheet. By June 30, current ratio fell from 1.93 to 1.62 and equity ratio from 55.9% to 50.2%; short borrowings rose to ¥500.297bn and CP to ¥143.382bn [Q1 pp.8–9]. Q1 short-term borrowing cash inflow was ¥326.690bn against treasury-share cash outflow ¥349.999bn [Q1 p.13]. Liquidity remains adequate, but the repurchase reduced financial flexibility; the March net-debt figure must not be treated as current post-buyback leverage.

[Reported fact] The ¥349.998bn FCSR acquisition occurred May 13, 2026, in FY2027/03. AR p.65 reports 14,516,700 shares acquired in the subsequent period, not in FY2026/03. The fact sheet's FY2026/03 total payout of 163.3% is therefore a fiscal-attribution distortion, not evidence of that year's realized cash payout. FY2026/03 dividends were ¥340/share, total ¥99.565bn and payout 36.2% [FY p.1]. September 7 disclosed the fourth FCSR tranche adjustment, increasing acquired shares by 96,300; final October share-count effects are not fully reconciled here [FCSR p.1].

[Reported fact / inference] Capex was ¥300.030bn against depreciation ¥276.206bn, and R&D ¥150.756bn, 3.0% of sales [FS, investment]. These investment measures are not identical to the ¥209.081bn PPE cash expenditure in the cash-flow statement [FY p.16]. ROE fell from 12.3% in FY2023/03 to 9.1% in FY2026/03 and ROA from 6.3% to 5.0%; IFIS headline ROIC is 6.8% [FS]. A calculated average-balance DuPont decomposition explains the ROE decline: net margin 6.47%→5.49%, asset turnover 0.980x→0.917x, leverage 1.933x→1.808x. Lower returns are not simply a leverage problem; profitability and asset productivity weakened too [FS, annual/balance; arithmetic from average beginning/end assets and equity].

[Company guidance] FUSION30 targets invested-capital turnover of 1.25x by March 2029 and at least 1.3x by March 2031. Company D-ROIC is pretax OP divided by receivables plus inventory plus fixed assets; it is not comparable with IFIS ROIC or a conventional after-tax WACC hurdle [S pp.13–14,37; I p.32, printed31]. [Analyst assumption] Against an illustrative 8–9% cost of equity, 9.1% ROE provides little excess-return cushion; this is not a company-disclosed capital-cost estimate. A numerical company WACC and group D-ROIC target were not located.

[Company guidance] Five-year OCF of ¥3tn is allocated to ¥1.8tn growth investment, at least ¥500bn dividends and at least ¥700bn combined buybacks/additional M&A, including the initial ¥350bn acquisition. The last amount is not a commitment to ¥700bn buybacks. Dividend policy transitions away from DOE toward stable, continuously growing dividends; FY2027/03 DPS guidance is ¥360 [S pp.31–34]. [Reported fact] Strategic holdings total ¥181.932bn, including ¥172.727bn listed holdings; FY2026/03 reductions in 13 listed names yielded ¥4.940bn [AR p.94]. A numerical elimination target was not found in that section.

Hard gates

[Reported fact / risk] Four US HVAC price-fixing class actions filed in April 2026 seek damages of unspecified amount; Daikin's May 14 notice says financial impact cannot reasonably be estimated [L pp.1–2]. Allegations are not findings of wrongdoing and are not themselves accounting-integrity failure. They remain an unquantified legal tail risk. AR pp.24–26 also identify environmental/refrigerant risks; absence of a quantified PFAS exposure in this review is not proof of no liability. FY2026/03 AHT impairment was ¥11.849bn, and acquisition-related valuation sensitivity remains an audit focus [AR pp.118,183].

IR and management credibility

[Reported fact / inference] The May 2023 latter-half FUSION25 plan targeted ¥500bn OP and 11% margin for March 2026; actuals were ¥414.991bn and 8.3%. The current plan acknowledges weak residential/heat-pump demand, competition, inadequate price/cost responses and delayed investment returns [P p.1; S pp.7–9]. Revenue exceeded the ¥4,550bn target, but that did not translate into the promised returns: a reason to discount the new margin targets until demonstrated.

[Reported fact] May 12 introduced FUSION30; August 4 materials provide regional KPIs and explicit price/cost bridges, and the September 28 English integrated report explains D-ROIC and capital allocation. Groupwide Solutions-ratio disclosure is expected to begin with Q2 results; current regional/sub-business ratios must not be mistaken for a comparable group series [Q-JP p.16; T p.8; I pp.29–34]. Disclosure quality is useful; delivery credibility remains mixed.

Valuation and scenarios

[External estimate] IFIS one-year-forward consensus PER is 19.80x versus recent mean 21.11x, −0.66σ; PBR is 1.99x versus mean 2.05x, −0.43σ. IFIS EV/EBITDA is 9.01x forecast and 9.29x actual; forecast dividend yield is 1.69% [FS, valuation]. Mean-band reference prices of ¥22,755 (PER) and ¥22,022 (PBR) imply only 6.6% and 3.2% price appreciation; neither is intrinsic value.

Why the market might be right: [Inference] lower ROE, several initial-guidance misses, worsening US mix, Chinese demand contraction and declining consensus justify a discount. A 19.3% decline from the high is not proof of mispricing.

Share-count and EPS reconciliation

[Reported fact] FY2026/03 primary EPS is ¥939.92; FY2027/03 company EPS guidance is ¥949.32. IFIS shows ¥963.73 and ¥973.43, respectively [FY pp.1–2; Q1 p.1; FS]. The primary FY2026/03 weighted average was 292.823m shares; IFIS values approximately imply the Q1 average of 285.588m. June 30 issued shares less treasury were 278.335408m [Q1 p.2]. Thus official-guidance PER is 22.48x, versus IFIS's adjusted-company-forecast 21.93x and its distinct forward-consensus 19.80x. These are different bases, not interchangeable competing readings of one PER.

[Inference] Using June-end shares as an illustrative fixed denominator, unchanged NP guidance of ¥278bn would imply EPS ¥998.79 and PER 21.37x. This is analyst arithmetic, not revised company EPS guidance. Later FCSR settlements may change that denominator; no additional buybacks are assumed in scenarios.

Twelve-month price scenarios using FY2028/03 earnings

All scenarios below are analyst assumptions, not company guidance or IFIS target prices. The EPS denominator is held at the June-end 278.335408m shares for consistency; EPS therefore corresponds to NP of approximately ¥361.8bn, ¥306.2bn and ¥250.5bn. IFIS FY2028/03 consensus NP of ¥327.365bn would imply ¥1,176.15 EPS on that same denominator. Base deliberately discounts consensus for execution and earnings-quality risk.

[Inference] Bull needs material margin and mix improvement; base allows modest underlying growth plus the share-count benefit; bear assumes cost pressure and weaker demand overwhelm pricing. Multiples are taken from the stock's recent forward-consensus band but applied to explicit next-year earnings as scenario assumptions, not an identical time-interpolated IFIS valuation method. Returns exclude dividends; adding one ¥360 forecast annual dividend to base gives approximately 10.5%, not a guaranteed total return. No probability-weighted expected return is claimed.

[Inference] The present price needs EPS ¥1,011 at the 21.11x mean PER. That is close to the illustrative buyback-adjusted current guidance EPS, so the price does not require FUSION30's distant targets to be fully achieved; equally, there is no large band-based cushion. IFIS's 19.80x measure implies approximately ¥1,078 of blended forward EPS, not the same as FY2028/03 EPS.

Listed HVAC competitors: whole-company context, not a pure-play valuation average

Secondary sources: Yahoo quote pages for 6503 and 7011, October 16 quotes; 6503 financials. MHI business profit ¥432.218bn / revenue ¥4,974.168bn from its Financial Report 2026, p.13; its measure includes equity-accounted earnings and other income/expenses. Both are HVAC competitors but diversified groups, with MHI's defense/power businesses particularly limiting comparability. All PER columns use company forecasts, not trailing PER; only Daikin's separate own-band discussion uses forward consensus. These are not harmonized IFRS/J-GAAP peer margins and do not establish Daikin fair value. Fujitsu General's quote is stale/non-trading and has no forecast PER, so it is excluded rather than treated as a live listed valuation peer.

Bull case

• [Company guidance / inference] Price/cost measures and solutions mix lift margins toward 10% by March 2029; operating leverage then makes FY2028/03 consensus ¥500bn OP plausible [S pp.13–20; FS, consensus].
• [Reported fact / inference] Applied local-currency growth of 17%, modular capacity +150%, and improving European heating demand provide measurable recovery avenues, but conversion to incremental group OP still needs proof [Q pp.9,11; Phoenix release].

Bear case

• [Reported fact / inference] Q1 profit excluding the tariff refund did not grow; US mix deterioration and China's −12% local-currency sales can offset pricing [Q pp.6,10; T p.15].
• [Reported fact / inference] Debt-funded repurchase adds financial exposure while litigation losses are unquantified and acquired-business returns remain uncertain [Q1 p.13; L p.2; AR pp.118,183].
• [External estimate / inference] FY2028/03 estimates keep falling from ¥500.047bn OP; a rerating toward the lower band would outweigh the 1.69% yield [FS, consensus/valuation].

Catalysts

[Reported fact / timing inference] Price is above its 25-day average ¥20,882 but below the 75-day ¥22,300 and 200-day ¥21,487; three-month return −14.2%, one-year TOPIX-relative return −5.27 points [FS, price]. This is a tentative rebound inside a weak intermediate trend, not a rating determinant. The August 5 earnings selloff reported by Nikkei/Kabutan is consistent with reported NP decline and the subsequent broker-target cuts, but the entire three-month drawdown cannot be attributed to one event [Q1 p.1; snapshot pages/report_topix.html].

What would change the rating

• Upgrade: [Analyst decision rule] comparable HVAC OP growth turns positive excluding FX and material refunds, Q2 demonstrates margin recovery, and FY2028/03 OP estimates stop falling; alternatively a materially cheaper entry with unchanged earnings prospects. A price around ¥19,000 would offer approximately 22% upside to the same base value, but is not an automatic Buy.
• Downgrade: [Analyst decision rule] company reduces ¥436bn FY2027/03 OP guidance, FY2028/03 consensus falls below ¥450bn without offsetting valuation relief, or deteriorating cash conversion accompanies continued buyback/M&A leverage.
• Thesis invalidated: [Analyst decision rule] a material adverse accounting finding, liquidity deterioration or quantified litigation loss materially alters financial capacity; any renewed Buy assessment must rerun the hard gates.

Monitoring

Scorecard

Scores are analyst judgments, not mechanically calculated valuation facts.

Fact-sheet flags

Computed by factsheet.mjs. Each flag is a prompt to investigate, not a conclusion.

• ▲amberreceivables-outpacing-sales receivables grew 18.0% in 2026/03 (856,542 to 1,011,104) against sales growth of 5.5%
• ▲amberpayout-over-earnings Total payout 163.3% of net profit in 2026/03 (dividends 99,565, buybacks 349,998)

Sources and limitations

Source keys below are ordered newest publication first; page references are PDF page indices. Earnings-release attachment printed pages are generally index minus two. Integrated Report printed pages are generally index minus one. Financial amounts in this report are billions of yen unless stated otherwise.

• FS, October 17 snapshot / October 16 market data: [factsheet.md](factsheet.md), [factsheet.json](factsheet.json), generated with node skills/ifis-equity-analyst/scripts/factsheet.mjs 6367; snapshot ../../2026-10-17/snapshot.json has errors: []. Raw sources referenced by FS include feeds/zaimu_fy_all.json, act_est_hist_n.json, cons_chart.json, segment_4q.json, zaimu_bs.json and valuation feeds. This report overrides the two EPS and payout basis issues described above; generated artifacts remain unmodified.
• Phoenix, October 14: official capacity announcement.
• I, September 28 English publication: Integrated Report 2026, especially pp.7–13,29–37. Japanese extraction was garbled; readable official English used.
• FCSR, September 7: fourth adjustment notice, p.1.
• Q / Q-JP / T, August 4: Q1 presentation, Japanese original, official briefing transcript.
• Q1, August 4: ../../2026-10-17/filings/2027-03_Q1_短信_20260804.pdf, especially pp.1–2,4–9,12–19; public filing.
• AR, June 24: ../../2026-10-17/filings/2026-03_FY_有報_20260624.pdf, especially pp.2,24–26,65,94–95,115–119,155–156,182–185. Targeted sections read, not the full report.
• L, May 14: US litigation notice, pp.1–2.
• FY, May 12: ../../2026-10-17/filings/2026-03_FY_短信_20260512.pdf, pp.1–2,4–6,16,18,24. S, May 12: FUSION30 presentation.
• P, May 31, 2023: FUSION25 latter-half plan, p.1.
• Current official IR calendar; public disclosure index, newest listed September 7. Snapshot disclose/news pages and targeted public searches found no later earnings release or forecast revision through this review; this is not a guarantee of exhaustive TDnet coverage.
• Peer sources are linked alongside the comparison; their dates and accounting definitions are explicit. No fresh peer IFIS snapshots were available. Conglomerate mix makes this a weak relative-valuation anchor.
• Kabutan's August 5 news page returned HTTP403; search result, Nikkei headline and primary results used for context. No causal attribution beyond the observed evidence is assumed.
• Unknowns: organic growth after acquisition/FX effects; tariff-refund recurrence and after-tax EPS; final FCSR-adjusted October denominator; quantified group order/backlog and AI contribution; litigation/environmental loss exposure; numerical company WACC/D-ROIC hurdle. These constrain confidence but do not prevent the provisional Hold.
• This is research, not individualized investment advice.